Goldman Sachs invests $20 M in China biotech firm

ChinaEnterprise Innovation — Goldman Sachs recently completed a $20 million investment in Ascletis, a China-based biotechnology company focused on innovative drug development. Within the past two months, Ascletis has completed two rounds of financing, with the first round of $35 million investment led by C-Bridge Capital, Tasly Pharmaceutical, and Pavilion Capital.

Goldman Sachs eyes China’s mobile content market with investment in Wandoujia

Chinese mobile content search engine and Android app store Wandoujia today announced it closed its series B round of financing with a follow-on investment from US investment bank Goldman Sachs. The undisclosed amount of funding comes just after Wandoujia’s $120 million funding led by Japanese mobile telco SoftBank. Wandoujia says this is Goldman Sachs’ first investment in a Chinese mobile internet company. Other Goldman Sachs investments in Chinese online firms include ebook platform Shanda Cloudary and Shanghai-based pet product store Boqii.